Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Open-Label Extension Study of Tobramycin Inhalation Powder (TIPnew) in Cystic Fibrosis
2008-004764-39Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tobramycin in cystic fibrosis (CF) and Pseudomonal infection, sponsored by Novartis. Primary endpoint: Safety. Started Jan 2009; status: completed.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on 2008-004764-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004764-39.